Swedish pharmaceutical contract development and manufacturing organization (CDMO) Recipharm has signed two separate agreements to acquire Kemwell’s pharmaceutical CDMO businesses.
Kemwell has integrated facilities in India, Sweden and the US and a portfolio of services for sterile and non-sterile products from preformulation to commercial supply worldwide. It offers expertise in inhaled, nasal, oral, parenteral and topical dosage forms.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
